SCHEMBL4218151

SCHEMBL4218151

O=C(O)c1ccc(-c2ccc3c(c2)OCO3)cc1Nc1ccc(F)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 0.52
CASP3 P42574 1/20 0.50
SENP8 Q96LD8 1/20 0.50
SENP7 Q9BQF6 1/20 0.50
SENP6 Q9GZR1 1/20 0.50
MEN1 O00255 4/20 0.49
FABP3 P05413 1/20 0.49
FABP4 P15090 1/20 0.49
FABP5 Q01469 1/20 0.49
GRIK1 P39086 1/20 0.49
USP2 O75604 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
ALOX15 P16050 1/20 0.49
MAPK1 P28482 1/20 0.49
CYP2C19 P33261 1/20 0.49
HSD17B10 Q99714 1/20 0.49
CLK4 Q9HAZ1 1/20 0.49
RAB9A P51151 7/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4220308 0.93 MAOB (0.50) KMT2AMEN1MAPK1HSD17B10RAB9A
SCHEMBL4217357 0.85 KMT2A (0.54) KMT2ACASP3SENP8SENP7SENP6
SCHEMBL4223512 0.85 MAPT (0.54) KMT2ACASP3SENP8SENP7SENP6
SCHEMBL4223507 0.85 MAPT (0.54) KMT2ACASP3SENP8SENP7SENP6
SCHEMBL4226484 0.84 XDH (0.54) GRIK1MAPTXDHSLC22A12AKR1C3
SCHEMBL4227799 0.84 GRIK1 (0.53) KMT2AMEN1FABP3FABP4FABP5
SCHEMBL2272852 0.83 CASP3 (0.57) KMT2ACASP3SENP8SENP7SENP6
SCHEMBL4215664 0.80 ACLY (0.52) FABP4GRIK1MAPTXDHSLC22A12
SCHEMBL4212903 0.80 MEN1 (0.51) KMT2AMEN1FABP3FABP4FABP5
SCHEMBL13877069 0.80 SMN1; SMN2 (0.47) KMT2AMEN1CYP1A2MAPK1CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8327467-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2012-12-11 US disclosed
EP-1860098-B1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO LTD (JP) 2012-11-14 EP disclosed
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-04-23 US disclosed
EP-1860098-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-11-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP11, MMP3 KMT2A 2524/4885CASP3 153/4885SENP8 2906/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.